Rhythm Pharmaceuticals, Inc.
Undisclosed program
Countdown
177days
Catalyst readout · ~ Dec 31, 2026 estimated
What's at stake
A key catalyst for Undisclosed program (its lead indication) is expected ~ Dec 31, 2026.
Primary source
· SEC 8-K
verified 15h ago
“On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired hypothalamic obesity in first quarter of 2026”